April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Vla-1 is Directly Involved in Lymphangiogenesis
Author Affiliations & Notes
  • S. Grimaldo
    Optometry, University of California, Berkeley, Berkeley, California
  • D. Yuen
    Optometry, University of California, Berkeley, Berkeley, California
  • L. Chen
    Optometry, University of California, Berkeley, Berkeley, California
  • Footnotes
    Commercial Relationships  S. Grimaldo, None; D. Yuen, None; L. Chen, None.
  • Footnotes
    Support  This work is supported in part by research grants from NIH, DoD, and University of California at Berkeley (LC).
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 34. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Grimaldo, D. Yuen, L. Chen; Vla-1 is Directly Involved in Lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 2010;51(13):34.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : In the inflamed and lymphatic-rich corneas, the transplantation rejection rate can be as high as 90%. Unfortunately, many patients who are blind from corneal diseases fall in this category after inflammatory, traumatic, or chemical insults. To date, there is no effective treatment for these patients. This study is to investigate the specific roles of VLA-1 (very late antigen 1; also known as alpha1beta1 integrin) in the processes of lymphangiogenesis both in vitro and in vivo.

Methods: : In vitro human lymphatic endothelial cell (LEC) culture model was used to study the expression of VLA-1 in LECs by both RT-PCR and immunocytochemistry assays. The effect of VLA-1 depletion in LECs by small interference RNAs (siRNA) on LEC proliferation and tube formation were also analyzed. Additionally, murine in vivo suture-induced corneal inflammatory lymphangiogenesis model was used to study the effect of VLA-1 neutralizing antibody (provided by Covella Pharmaceuticals, Inc.) on the development of new lymphatic vessels in the inflamed corneas.

Results: : VLA-1 was expressed in human LECs at both mRNA and protein levels. Its down-regulation by siRNAs suppressed LEC proliferation as well as tube formation. This effect was also confirmed in the inflamed corneas after the antibody treatment.

Conclusions: : VLA-1 plays a direct role in the processes of lymphangiogenesis, holding the promise of uncovering new therapeutic targets for corneal inflammation and transplant rejection. It is hopeful that beyond its contributions to eye diseases, this study also will shed some light on the development of new therapeutic strategies for other lymphatic-related disorders in the body.

Keywords: neovascularization • immune tolerance/privilege • immunomodulation/immunoregulation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.